President of the Salk Institute for Biological Studies, Elizabeth Blackburn has announced her retirement next summer, after just over two years in the role.
New start-up companies are constantly commercialising new technologies and services. Genomics is ripe for investment right now.
A group of well-known companies aims to be the first to analyse brain scans together with genomic, clinical and phenotypic data to study neurodegenerative diseases at a population level, then distil it down to an individual’s personal treatment plan.
Last year, the pharma industry’ biggest trade group raised millions to change the conversation about drug pricing.
Companion DX is one of at least six clinical labs mired in bankruptcy court after Medicare alleged they improperly billed the government for unnecessary tests.
As former leader and founder Nessan Bermingham walks away from Intellia Therapuetics, it has named John Leonard as its new president and chief.
Copenhagen Center for Glycomics has announced a collaboration with Desktop Genetics to analyse their novel CRISPR assay.
So far this year, the top five selling drugs have raked in a combined value of $48 billion, and we tell you exactly why they have been so successful.
Project on Government Oversight says Amicus Therapeutics CEO John Crowley sent Gottlieb a friendly note just months before their drug was FDA fast-tracked.
Several individual investors from Illumina have invested in an open-source genomics database that uses the same technology employed by Bitcoin.
The US Food and Drug Administration has published two draft guidelines outlining the regulatory requirements for molecularly guided personalised treatments.
Christmas may come early for some plucky bio-techs, as a new pool of funding is being made available by venture capital Andreesen Horowitz.
The five-year drug discovery partnership will be focused on Messenger RNA (mRNA) translation.